EFG
GILD icon

Ethos Financial Group’s Gilead Sciences GILD Stock Holding History

Ethos Financial Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Sell
3,022
-56
-2% -$7.38K 0.03% 416
2026
Q1 		$427K Buy
3,078
+1,416
+85% +$198K 0.03% 341
2025
Q4 		$204K Sell
1,662
-497
-23% -$60.4K 0.02% 474
2025
Q3 		$240K Sell
2,159
-597
-22% -$67.9K 0.02% 406
2025
Q2 		$306K Buy
+2,756
New +$293K 0.03% 337

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ethos Financial Group's GILD Position: Q2 2026 in Review

Ethos Financial Group reduced its Gilead Sciences (GILD) stake by 1.8% in Q2 2026, selling an estimated $7.38K and leaving 3,022 shares worth $401K. The position accounts for 0.03% of the portfolio, ranked #416.

Ethos Financial Group first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $427K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Ethos Financial Group held 3,022 shares of Gilead Sciences worth $401K as of Q2 2026.
  • Ethos Financial Group sold 56 Gilead Sciences shares in Q2 2026, an estimated $7.38K.
  • Gilead Sciences made up 0.03% of Ethos Financial Group's portfolio in Q2 2026, its #416 holding.
  • Ethos Financial Group first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • Ethos Financial Group's Gilead Sciences position peaked at $427K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Ethos Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.